New Delhi metallo-β-lactamase: a cautionary tale

Muir, Alison; Weinbren, M.

doi:10.1016/j.jhin.2010.02.005

Cited by 44 publications

(38 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Any Enterobacteriaceae isolate that exhibits a minimum inhibitory concentration (MIC) above the epidemiological cut-off or with clinical resistance to ertapenem, imipenem or meropenem should trigger further testing [12,27] Carbapenemase activity can be screened by using the modified Hodge test [2,[10][11][12] and, as with other metallo-beta-lactamases, synergy can be detected by EDTA-imipenem disc or Etest [1,2,10-12,]. Widely used automated susceptibility systems show good sensitivity but poor specificity for detection of carbapenem resistance mediated by NDM-1 and other carbapenemases [13]. Further evaluation of in-house and commercial test systems with larger numbers of NDM-1-producing strains are desirable, given the variable phenotypic expression of carbapenemase activity, as observed with strains producing KPC-and VIM-like enzymes [3,6,11,14,15,27].…”

Section: Laboratory Detection and Identificationmentioning

confidence: 99%

New Delhi metallo-beta-lactamase 1–producing Enterobacteriaceae: emergence and response in Europe

et al. 2010

View full text Add to dashboard Cite

Acquired carbapenemases confer extensive antibiotic resistance to Enterobacteriaceae and represent a public health threat. A novel acquired carbapenemase, New Delhi metallo-beta-lactamase 1 (NDM-1), has recently been described in the United Kingdom and Sweden, mostly in patients who had received care on the Indian subcontinent. We conducted a survey among 29 European countries (the European Union Member States, Iceland and Norway) to gather information on the spread of NDM-1-producing Enterobacteriaceae in Europe, on public health responses and on available national guidance on detection, surveillance and control. A total of 77 cases were reported from 13 countries from 2008 to 2010. Klebsiella pneumoniae was the most frequently reported species with 54%. Among 55 cases with recorded travel history, 31 had previously travelled or been admitted to a hospital in India or Pakistan and five had been hospitalised in the Balkan region. Possible nosocomial acquisition accounted for 13 of 77 cases. National guidance on NDM-1 detection was available in 14 countries and on NDM-1 control in 11 countries. In conclusion, NDM-1 is spreading across Europe, where it is frequently linked to a history of healthcare abroad, but also to emerging nosocomial transmission. National guidance in response to the threat of carbapenemase-producing Enterobacteriaceae is available in approximately half of the surveyed European countries. Surveillance of carbapenemase- producing Enterobacteriaceae must be enhanced in Europe and effective control measures identified and implemented.

show abstract

Section: Laboratory Detection and Identificationmentioning

confidence: 99%

New Delhi metallo-beta-lactamase 1–producing Enterobacteriaceae: emergence and response in Europe

et al. 2010

View full text Add to dashboard Cite

show abstract

“…como fluoroquinolonas, aminoglucósidos, macrólidos y al trimetropin-sulfametoxazol; inclusive, algunos se han reportado como panresistentes (5)(6)(7)(8) .…”

Section: Mensajes Claveunclassified

Klebsiella pneumoniae nueva Delhi metalo-betalactamasa en el hospital nacional Dos de Mayo. Lima, Perú

Resurrección-Delgado

Montenegro-Idrogo

Chiappe-Gonzalez

et al. 2017

Rev Peru Med Exp Salud Publica

View full text Add to dashboard Cite

RESUMENLa emergencia de enterobacterias productoras de carbapenemasas de tipo Nueva Delhi Metalo beta-lactamasas (NDM), representan, hoy en día, un verdadero problema de salud pública mundial. La presencia de este mecanismo de resistencia limita o anula las opciones terapéuticas para combatir a estas bacterias. En Latinoamérica, las cifras son cada vez más elevadas, pues se reportan en Guatemala, Colombia, Chile, Argentina, entre otros. Perú no ha descrito, hasta la fecha, la presencia de este patrón de resistencia; sin embargo, desde hace varios años se presume de su existencia. Se describen nueve casos de Klebsiella pneumoniae NDM, como agentes infecciosos o colonizantes, en pacientes críticamente enfermos, en su mayoría con patología neuroquirúrgica, del Hospital Nacional Dos de Mayo, en Lima -Perú. Los pacientes de la serie descrita a continuación, representan los primeros reportes de Klebsiella pneumoniae NDM en el Perú. Palabras clave: Klebsiella pneumoniae, Nueva Delhi Metalo beta-lactamasa, Enterobacteriaceae, carbapenemasa, Latinoamérica. (fuente: DeCS BIREME). Klebsiella pneumoniae NEW DELHI METALO-LACTAMASE IN A PERUVIAN NATIONAL HOSPITAL ABSTRACTThe emergence of Enterobacteria producing carbapenemases of type New Delhi Metalo beta-lactamases (NDM), represent, today, a real problem of world public health. The presence of this resistance mechanism limits or nullifies the therapeutic options to combat these bacteria. In Latin America, the figures are getting higher, as they are reported in Guatemala, Colombia, Chile, Argentina, among others. Peru has not, to date, described the presence of this resistance pattern; however for several years it has been presumed to exist. Nine cases of Klebsiella pneumoniae NDM are described, as infectious or colonizing agents, in critically ill patients, mostly with neurosurgical pathology, of Hospital Nacional Dos de Mayo in Lima -Peru. The patients in the series described below represent the first reports of Klebsiella pneumoniae NDM in Peru.

show abstract

“…[4] A patient having infection with Escherichia coli expressing NDM-1 was reported in May 2010 in the United Kingdom, who had a history of visiting India 18 months ago for undergoing dialysis. [5] In June 2010, three isolates of Enterobacteriaceae family bearing this resistance mechanism were reported in the US, which were from patients who had recently received medical care in India. [6] In July 2010, isolation of three cases of Acinetobacter baumanii bearing blaNDM-1 from the intensive care unit of a hospital in Chennai, India, were reported by a team from New Delhi.…”

Section: Origin and Spreadmentioning

confidence: 99%

New Delhi metallo-beta-lactamase-1: A weapon for the newly emerging drug-resistant bacteria

Padhi¹

2017

Indian J Med Sci

View full text Add to dashboard Cite

The world has seen the emergence of many micro-organisms in the recent past which can curb the human population with their newly built genetic make-up. The latest addition to this list of panic creating organisms is, bacteria encoding the gene for New Delhi metallo-beta-lactamase (NDM)-1. NDM-1 is an enzyme that can hydrolyse and inactivate carbapenems, which are used as a last resort for the treatment of multiresistant bacterial infections. Name of these bacteria were not found in the medical literature before December 2009, because of which it can take the credit of becoming a powerful emerging bacteria which are difficult to treat. Besides Escherichia coli and Klebsiella pneumoniae, other bacterial strains have also expressed the gene for NDM-1, which are detected in many countries.

show abstract

New Delhi metallo-β-lactamase: a cautionary tale

Cited by 44 publications

References 3 publications

New Delhi metallo-beta-lactamase 1–producing Enterobacteriaceae: emergence and response in Europe

New Delhi metallo-beta-lactamase 1–producing Enterobacteriaceae: emergence and response in Europe

Klebsiella pneumoniae nueva Delhi metalo-betalactamasa en el hospital nacional Dos de Mayo. Lima, Perú

New Delhi metallo-beta-lactamase-1: A weapon for the newly emerging drug-resistant bacteria

Contact Info

Product

Resources

About